Stock of the Day: Can Vericel Corp’s Tomorrow be Different? The Stock Declines Again

Stock of the Day: Can Vericel Corp's Tomorrow be Different? The Stock Declines Again

The stock of Vericel Corp (NASDAQ:VCEL) is a huge mover today! About 263,612 shares traded hands. Vericel Corp (NASDAQ:VCEL) has declined 33.93% since April 6, 2016 and is downtrending. It has underperformed by 35.89% the S&P500.
The move comes after 8 months negative chart setup for the $48.43M company. It was reported on Nov, 8 by Barchart.com. We have $1.85 PT which if reached, will make NASDAQ:VCEL worth $5.33M less.

Analysts await Vericel Corp (NASDAQ:VCEL) to report earnings on November, 11.

Vericel Corp (NASDAQ:VCEL) Ratings Coverage

Out of 2 analysts covering Vericel (NASDAQ:VCEL), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. Vericel has been the topic of 2 analyst reports since March 11, 2016 according to StockzIntelligence Inc. The stock of Vericel Corp (NASDAQ:VCEL) earned “Buy” rating by Needham on Friday, March 11. The stock has “Neutral” rating given by Bank of America on Tuesday, April 5.

According to Zacks Investment Research, “Vericel Corporation is focused on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two autologous cell therapy products in the United States: Carticel (R) for the treatment of cartilage defects in the knee, and Epicel (R) for the treatment of severe burns. It is also developing MACI (TM) for the treatment of cartilage defects in the knee, and ixmyelocel-T for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. Vericel Corporation, formerly Aastrom Biosciences, Inc., is based in United States.”

More recent Vericel Corp (NASDAQ:VCEL) news were published by: Marketwatch.com which released: “Vericel Corp. NASDAQ: VCEL” on November 28, 2014. Also Seekingalpha.com published the news titled: “Vericel Corporation’s (VCEL) CEO Nick Colangelo on Q3 2016 Results – Earnings …” on November 08, 2016. Quotes.Wsj.com‘s news article titled: “News Vericel Corp.VCEL” with publication date: November 27, 2014 was also an interesting one.

VCEL Company Profile

Vericel Corporation (Vericel), formerly Aastrom Biosciences, Inc., incorporated on March 24, 1989, is a commercial-stage biopharmaceutical firm dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Firm operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment. Vericel markets two autologous cell therapy products in the United States: Carticel (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns approximately 30% of total body surface area (TBSA).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment